Real-world use of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a global observational study enrolling about 500 adults who have FRα-positive platinum-resistant cancer and are to receive mirvetuximab soravtansine as monotherapy. Researchers will collect real-world data on treatment patterns, effectiveness, patient characteristics, biomarker testing, and health-related quality of life. The study will track outcomes as patients receive MIRV within the approved local labeling and standard care. Participation requires informed consent and patient-reported outcome data collection. No interventional procedures beyond routine treatment are involved.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants scheduled to be treated with mirvetuximab soravtansine in accordance with the local label, with treatment decision made independently before study enrollment
* Signed informed consent and willingness to comply with study requirements including patient-reported outcome data collection

Exclusion Criteria:

* Any condition included in the contraindications section of the approved local mirvetuximab soravtansine label
* Participation in a concurrent interventional clinical trial from enrollment throughout the study
* Unwillingness or inability to comply with study requirements

Where it's running

• Medizinische Universitaet Wien /ID# 282657
  Vienna, Austria Recruiting

Study contacts

• Study coordinator: Farah Khallaf
• Email: farah.khallaf@abbvie.com
• Phone: +1 (630) 2636202

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AZD5335 versus mirvetuximab or chemotherapy for FRα-high and FRα-low platinum-resistant ovarian, fallopian tube, or peritoneal cancer

  This will test whether AZD5335 works better than mirvetuximab for FRα-high tumors or better than single-agent chemotherapy for FRα-low tumors in women with high-grade, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 95 sites Phase 3 AstraZeneca · Birmingham, Alabama and 298 other locations · NCT07218809

• Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 212 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 263 other locations · NCT07213804

• Mirvetuximab soravtansine combined with bevacizumab or carboplatin for FRα‑positive ovarian cancer

  This Phase 2 trial tests whether giving intravenous mirvetuximab soravtansine with bevacizumab or carboplatin is safe and can change disease activity in adults with folate receptor alpha (FRα)–positive high‑grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 85 sites Phase 2 AbbVie · La Jolla, California and 85 other locations · NCT07059845

• Combining carboplatin with mirvetuximab soravtansine before surgery for FRα-positive advanced serous ovarian, fallopian tube, or primary peritoneal cancer

  This will test whether giving mirvetuximab soravtansine with carboplatin before surgery helps people with newly diagnosed FRα-positive advanced-stage serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 71 sites Phase 2 AbbVie · Birmingham, Alabama and 72 other locations · NCT06890338

• Mirvetuximab soravtansine for platinum-resistant high-grade ovarian, fallopian tube, and primary peritoneal cancer with high folate receptor-alpha

  This trial tests whether intravenous mirvetuximab soravtansine helps people with platinum-resistant high-grade ovarian, fallopian tube, or primary peritoneal cancer whose tumors have high folate receptor-alpha.

  Recruiting at 52 sites Phase 2 AbbVie · Sarasota, Florida and 51 other locations · NCT06682988

• Carboplatin and Mirvetuximab for Advanced Ovarian Cancer Treatment

  This study is testing if a combination of carboplatin and mirvetuximab can help women with advanced ovarian cancer do better after their initial chemotherapy before surgery.

  Recruiting at 9 sites Phase 2 University of Alabama at Birmingham · Birmingham, Alabama and 8 other locations · NCT04606914

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.